BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Monday, May 6, 2024
See today's BioWorld
Home
» Viratherapeutics gets $4M for oncolytic VSV, as Mayo Clinic suspends its VSV phase I trial
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Viratherapeutics gets $4M for oncolytic VSV, as Mayo Clinic suspends its VSV phase I trial
June 26, 2015
By
Cormac Sheridan
No Comments
DUBLIN – Viratherapeutics GmbH raised €3.6 million (US$4 million) in a first closing of a series A round to complete preclinical research and to commence clinical trials of its lead oncolytic virus program, VSV-GP.
BioWorld